Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis

Pharmacological Research

Volumn 35, Issue 6, 1997, Pages 557-560

  Zeneroli, M L ^a   Venturini, I ^a   Stefanelli, S ^a   Farina, F ^a   Cosenza, R ^a   Miglioli, L ^a   Minelli, E ^a   Amedei, R ^a   Ferrieri, A ^b   Avallone, R ^a   Baraldi, M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Alfa Wassermann SpA   (Italy)

Author keywords

Benzodiazepine like compounds; Intestinal bacterial flora; Liver cirrhosis; Rifaximin

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; RIFAXIMIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031172532     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0198     Document Type: Article

References (18)

1. 1. Wildmann J, Vetter W, Ranadaler UB, Schmidt K, Maurer R, Mohler H. Occurrence of pharmacologically active BZD in trace amounts in wheat and potato. Biochem Pharmacol 1988; 37: 3549-59.
2. 2. Medina JH, Pena C, Levi de Stein M, Wolfman C, Paladini AC. Benzodiazepine-like molecules as well as other ligands for the brain benzodiazepine receptors, are relatively common constituents of plants. Biochem Biophys Res Comm 1989; 165: 547-53.
3. 3. Avallone R, Zanoli P, Corsi L, Cannazza G, Baraldi M. Benzodiazepine-like compounds and GABA in flower heads of Matricaria chamomilla. Phytother Res 1996; 10: 177-9.
4. 4. Avallone R, Corsi L, Zanoli P, Di Bella M, Monzani A, Venturini I, Zeneroli ML, Baraldi M. Sostanze ad attivita benzodiazepino-simile in alimenti e in droghe vegetali: implicazioni fisiologiche e patologiche. Acta Phytotherap (in press).
5. 5. Sangameswaran L, De Blas AL. Demonstration of the benzodiazepine-like molecules in the mammalian brain with a monoclonal antibody to benzodiazepines. Proc Natl Acad Sci USA 1985; 82: 5560-4.
6. 6. De Blas AL, Park D, Friedrich P. Endogenous benzodiazepine-like molecules in human, rat and bovine brains studied with a monoclonal antibody to benzodiazepines. Brain Res 1987; 413: 275-84.
7. 7. Unseld E, Klotz U. Benzodiazepines: are they of natural origin? Pharmaceut Res 1989; 6: 1-3.
8. 8. Zeneroli ML, Venturini I, Avallone R, Ardizzone G, Demartini M, Portella G, Baraldi M. Levels of endogenous benzodiazepine compounds in serum of liver cirrhosis patients with and without encephalopathy and in fulminant hepatic failure. Hepatology 1994; 19: 1431.
9. 9. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
10. 10. Olasmaa M, Rothstein JD, Guidotti A, Weber PJ, Paul SM, Spector S, Zeneroli ML, Baraldi M, Costa E. Endogenous benzodiazepine in human and animal hepatic encephalopathy. J Neurochem 1990; 55: 2015-23.
11. 11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
12. 12. Olasmaa M, Guidotti A, Costa E, Rothstein JD, Goldman ME, Weber PJ, Paul SM. Endogenous benzodiazepines in hepatic encephalopathy. Lancet 1989; 1: 491-2.
13. 13. Basile AS, Gammal SH, Jones EA, Skolnick P. GABA-A receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor complex ligand. Neurochemistry 1989; 53: 1057-63.
14. 14. Mullen KD, Martin JV, Mendelson WB, Bassett ML, Jones EA. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988; 1: 457-9.
15. 15. Yurdaydin C, Walsh TJ, Engler HD, Ha JH, Li Y, Jones EA, Basile AS. Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995; 679: 42-8.
16. 16. Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976; 17: 975-83.
17. 17. Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467-84.
18. 18. Effimiadi C, Deleo C, Schito GC. Treatment of hepatic encephalopathy with L/105. A new non-absorbable ryfamicin. Drug Exp Clin Res 1984; 10: 691-6.